Literature DB >> 16434714

Prevalence and association of PCR ribotypes of Clostridium difficile isolated from symptomatic patients from Warsaw with macrolide-lincosamide-streptogramin B (MLSB) type resistance.

Hanna Pituch1, Jon S Brazier2, Piotr Obuch-Woszczatyński1, Dorota Wultańska1, Felicja Meisel-Mikołajczyk1, Mirosław Łuczak1.   

Abstract

Isolates (79 in total) of Clostridium difficile obtained over a 2 year period from 785 patients suspected of having C. difficile-associated diarrhoea (CDAD) and being hospitalized in the University Hospital in Warsaw were characterized by toxigenicity profile and PCR ribotyping. Furthermore, their susceptibility to clindamycin and erythromycin was determined. Among the 79 C. difficile isolates, 35 were classified as (A+)B+, 1 as (A+)(B+)CDT+, 36 as (A-)B+ and 7 as (A-)B-. A total of 21 different PCR ribotypes was detected. Two main (A+)B+ strains circulated in our hospital: ribotype 014 and ribotype 046. Unexpectedly, the predominant PCR ribotype was type 017, a known (A-)B+ strain, and this accounted for about 45.5 % of all isolates cultured from patients with CDAD. Isolates belonging to PCR ribotype 017 were found in cases from epidemics of antibiotic-associated diarrhoea in the internal and surgery units. High-level resistance (MIC > or = 256 mg l(-1)) to clindamycin and erythromycin was found in 39 (49 %) of the C. difficile isolates. Interestingly, 34 (94 %) of macrolide-lincosamide-streptogramin B (MLSB) type resistance strains did not produce toxin A, but produced toxin B and were (A-)B+ ribotype 017. Thirty-seven of the high-level resistance strains harboured the erythromycin-resistance methylase gene (ermB). C. difficile isolates (2/29) that had high-level clindamycin and erythromycin resistance, and belonged to PCR ribotype 046, were ermB negative. These investigations revealed that the predominant C. difficile strain isolated from symptomatic patients hospitalized in University Hospital in Warsaw was MLSB-positive clindamycin/erythromycin-resistant PCR ribotype 017.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434714     DOI: 10.1099/jmm.0.46213-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  17 in total

1.  Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.

Authors:  Andre J Marozsan; Dangshe Ma; Kirsten A Nagashima; Brian J Kennedy; Yun Kenneth Kang; Robert R Arrigale; Gerald P Donovan; Wells W Magargal; Paul J Maddon; William C Olson
Journal:  J Infect Dis       Date:  2012-06-25       Impact factor: 5.226

Review 2.  Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.

Authors:  Patrizia Spigaglia
Journal:  Ther Adv Infect Dis       Date:  2016-02

3.  Molecular epidemiology of Clostridium difficile infection in a major chinese hospital: an underrecognized problem in Asia?

Authors:  Peter M Hawkey; Clare Marriott; Wen En Liu; Zi Juan Jian; Qian Gao; Thomas Kin Wah Ling; Viola Chow; Erica So; Raphael Chan; Katie Hardy; Li Xu; Susan Manzoor
Journal:  J Clin Microbiol       Date:  2013-07-31       Impact factor: 5.948

4.  Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018.

Authors:  Patrizia Spigaglia; Fabrizio Barbanti; Anna Maria Dionisi; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

5.  The emergence of Clostridium difficile PCR-ribotype 001 in Slovakia.

Authors:  O Nyc; M Krutova; A Liskova; J Matejkova; J Drabek; E J Kuijper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-17       Impact factor: 3.267

6.  Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease.

Authors:  D Wultańska; A Banaszkiewicz; A Radzikowski; P Obuch-Woszczatyński; G Młynarczyk; J S Brazier; H Pituch; A van Belkum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-26       Impact factor: 3.267

7.  Essential role of toxin A in C. difficile 027 and reference strain supernatant-mediated disruption of Caco-2 intestinal epithelial barrier function.

Authors:  P A Sutton; S Li; J Webb; K Solomon; J Brazier; Y R Mahida
Journal:  Clin Exp Immunol       Date:  2008-05-26       Impact factor: 4.330

8.  Comparison of polymerase chain reaction ribotyping, toxinotyping and nutritional aspects of toxin production of Clostridium difficile strains.

Authors:  Shanshan Zhu; Liming Zhang; Chunling Zhang; Xianjun Chen; Qi Chen; Zhaoyun Li
Journal:  Biomed Rep       Date:  2014-04-25

9.  Clostridium difficile in retail ground meat, Canada.

Authors:  Alexander Rodriguez-Palacios; Henry R Staempfli; Todd Duffield; J Scott Weese
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

10.  Characterization of Clostridium difficile isolates using capillary gel electrophoresis-based PCR ribotyping.

Authors:  A Indra; S Huhulescu; M Schneeweis; P Hasenberger; S Kernbichler; A Fiedler; G Wewalka; F Allerberger; E J Kuijper
Journal:  J Med Microbiol       Date:  2008-11       Impact factor: 2.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.